Ironwood Pharmaceuticals (IRWD) Operating Leases (2019 - 2026)

Ironwood Pharmaceuticals has disclosed Operating Leases across 8 years of filings, most recently posting $8.6 million for Q2 2026.

• In Q2 2026, Operating Leases fell 22.81% year-over-year to $8.6 million; the TTM figure through Jun 2026 stood at $8.6 million (down 22.81% YoY), while the FY2025 annual figure was $9.9 million, down 19.78% from the prior year.
• Operating Leases came in at $8.6 million for Q2 2026 at Ironwood Pharmaceuticals, down from $9.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $18.0 million in Q1 2022 to a low of $8.6 million in Q2 2026.
• Average Operating Leases over 5 years is $13.6 million, with a median of $13.7 million recorded in 2024.
• Year-over-year, Operating Leases retreated 9.22% in 2022 and fell 22.81% in 2026.
• Over 5 years, Operating Leases stood at $16.6 million in 2022, then retreated by 12.39% to $14.5 million in 2023, then declined by 15.4% to $12.3 million in 2024, then fell by 19.78% to $9.9 million in 2025, then dropped by 13.06% to $8.6 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $8.6 million in Q2 2026, $9.2 million in Q1 2026, and $9.9 million in Q4 2025.